Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · May 28, 2020

First-Line Pembrolizumab and Trastuzumab in HER2-Positive Esophageal, Gastric, or Gastroesophageal Junction Cancer

The Lancet Oncology

 

Additional Info

The Lancet Oncology
First-Line Pembrolizumab and Trastuzumab in HER2-Positive Oesophageal, Gastric, or Gastro-Oesophageal Junction Cancer: An Open-Label, Single-Arm, Phase 2 Trial
Lancet Oncol 2020 May 18;[EPub Ahead of Print], YY Janjigian, SB Maron, WK Chatila, et ak

Further Reading